Cytyc Gets Digene After Long Courtship, On Verge Of New Indication
This article was originally published in The Gray Sheet
Executive Summary
The payback on Cytyc's $554 mil. acquisition of Digene could get a quick boost from Digene's pending primary screening indication for DNA Pap for cervical cancer
You may also be interested in...
Digene Will Achieve Strategic Goals Faster Through Qiagen Merger, CEO Says
Human papillomavirus test maker Digene will expand its international presence and gain critical mass to help counter looming competition in the lucrative HPV test market by merging with Dutch molecular diagnostics firm Qiagen
Digene Will Achieve Strategic Goals Faster Through Qiagen Merger, CEO Says
Human papillomavirus test maker Digene will expand its international presence and gain critical mass to help counter looming competition in the lucrative HPV test market by merging with Dutch molecular diagnostics firm Qiagen
Digene Infrastructure Scale-Up For DNA Pap Could Follow Failed Cytyc Merger
Digene may decide to expand its sales infrastructure for marketing the HPV DNA Pap test as a primary screen for cervical cancer if its pending merger with Cytyc does not occur